Askeland FB, Haukås E, Slørdahl TS, Klostergaard A, Alexandersen T, Lysén A, Abdollahi P, Nielsen LK, Hermansen E, Schjesvold F (2025)
Isatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineligible multiple myeloma (REST): a multicentre, single-arm, phase 2 trial
Lancet Haematol, 12 (2), e120-e127
DOI 10.1016/S2352-3026(24)00347-8, PubMed 39909655

Costa LJ, Banerjee R, Mian H, Weisel K, Bal S, Derman BA, Htut MM, Nagarajan C, Rodriguez C, Richter J, Frigault MJ, Ye JC, van de Donk NWCJ, Voorhees PM, Puliafito B, Bahlis N, Popat R, Chng WJ, Ho PJ, Kaur G, Kapoor P, Du J, Schjesvold F, Berdeja J, Einsele H et al. (2025)
International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma
Leukemia, 39 (3), 543-554
DOI 10.1038/s41375-024-02482-6, PubMed 39870767

Slørdahl TS, Askeland FB, Hanssen MSS, Hov H, Sundt-Hansen SM, Lindahl S, Vethe NT, Hjorth-Hansen H, Fenstad MH, Waage A, Hjertner Ø, Schjesvold F, Sundan A (2025)
Combined Proteasome and Autophagy Inhibition in Relapsed/Refractory Multiple Myeloma-A Phase I Trial of Hydroxychloroquine, Carfilzomib, and Dexamethasone
EJHaem, 6 (1), e1091
DOI 10.1002/jha2.1091, PubMed 39866949